Corporate News

Concepta PLC (AIM:CPT),  the UK healthcare company and developer of a proprietary product targeted at the mobile health market and with a primary focus on women's fertility, confirms that the Annual Report and Accounts for the the year ended 31 December 2017, along with the Notice of Annual General Meeting ("AGM") and associated form of proxy will be sent to shareholders today, Tuesday 22 May.

The Company's AGM will be held at The Exchange, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ at 9.30am on Thursday, 14 June 2018.

The Annual Report and Accounts, Notice of AGM and the associated form of proxy are also available on the Company's website at www.conceptaplc.com.  

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

Notes to Editors

Concepta PLC

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility^† in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and human chorionic gonadotropin (hCG) hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing relationships with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future. 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H2 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

^†Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.